Article Text

Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study
  1. Christopher R Wilcox1,
  2. Nazrul Islam2 and
  3. Hajira Dambha-Miller1
  1. 1Primary Care Research Centre, University of Southampton, Southampton, UK
  2. 2Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, Oxfordshire, UK
  1. Correspondence to Dr Christopher R Wilcox; christopher.wilcox{at}doctors.org.uk

Abstract

Introduction Recent evidence suggests that influenza vaccination may offer protection against COVID-19 severity. Our aim was to quantify the association between influenza vaccination status and risk of hospitalisation or all-cause mortality in people diagnosed with COVID-19.

Methods A retrospective cohort study using routinely collected health records from patients registered to a General Practitioner (GP) practice in South West England within the Electronic Care and Health Information Analytics database. The cohort included 6921 people with COVID-19 during the first wave of the pandemic (1 January–31 July 2020). Data on influenza vaccination, hospitalisation and all-cause mortality were ascertained through linked clinical and demographic records. We applied propensity score methods (stabilised inverse probability of treatment weight) to quantify the association between influenza vaccination status and COVID-19 outcomes (hospitalisation or all-cause mortality).

Results 2613 (38%) participants received an influenza vaccination between 1 January 2019 and COVID-19 diagnosis. Receipt of influenza vaccination was associated with a significantly lower odds of hospitalisation or all-cause mortality (adjusted OR: 0.85, 95% CI 0.75 to 0.97, p=0.02), and 24% reduced odds of all-cause mortality (adjusted OR: 0.76, 95% CI 0.64 to 0.90).

Discussion Influenza vaccination was associated with a 15%–24% lower odds of severe COVID-19 outcomes. The current UK influenza vaccination programme needs urgent expansion as an integral component of the ongoing response plans to the COVID-19 pandemic.

  • COVID-19
  • respiratory infection
  • infection control
  • innate immunity

Data availability statement

Data are available on reasonable request. Anonymised individual level data used in this study was extracted from the Care and Health Information Analytics (CHIA) database. Direct requests for data sharing can be made to CHIA.

https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available on reasonable request. Anonymised individual level data used in this study was extracted from the Care and Health Information Analytics (CHIA) database. Direct requests for data sharing can be made to CHIA.

View Full Text

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • CRW and NI are joint first authors.

  • Contributors CRW wrote the first draft of the manuscript, carried out data analysis and revised the manuscript. NI lead the data analysis and revised the manuscript. HD-M contributed to the inception of the study, designed the study methods, edited and contributed to subsequent versions of the manuscript. HDM is guarantor. All authors had access to, and verified, the underlying data.

  • Funding HD-M is a National Institute for Health Research (NIHR) funded Academic Clinical Lecturer at the University of Southampton and has received NIHR School of Primary Care Research (SPCR) funding to support her COVID-19 work (SPCR2014-10043). CW is an NIHR-funded Academic Clinical Fellow at the University of Southampton. Open access funding for publication of this article was provided by the University of Southampton. NI received salary support from the Nuffield Department of Population Health at the University of Oxford.

  • Disclaimer The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the UK NIHR or the Department of Health and Social Care.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.